Indications And Dose
MENVEO ® Primary immunisation against Neisseria meningitidis ▶BY INTRAMUSCULAR INJECTION ▶Child 13–15 years: 0.5 mL for 1 dose, dose preferably injected into deltoid region Immunisation against Neisseria meningitidis in an unimmunised patient ▶BY INTRAMUSCULAR INJECTION ▶Child 10–17 years: 0.5 mL for 1 dose, booster dose is not required ▶Adult 18–24 years: 0.5 mL for 1 dose, booster dose is not required Immunisation against Neisseria meningitidis in those at risk of exposure to prevent invasive disease ▶BY INTRAMUSCULAR INJECTION ▶Child 3–11 months: 0.5 mL every month for 2 doses, dose preferably injected into deltoid region ▶Child 1–17 years: 0.5 mL for 1 dose, dose preferably injected into deltoid region ▶Adult: 0.5 mL for 1 dose, dose preferably injected into deltoid region Patients attending university for the first time (who have not received the routine meningococcal groups A with C and W135 and Y conjugate vaccine over the age of 10 years) ▶BY INTRAMUSCULAR INJECTION ▶Adult 18–24 years: 0.5 mL for 1 dose NIMENRIX ® Primary immunisation against Neisseria meningitidis ▶BY INTRAMUSCULAR INJECTION ▶Child 13–15 years: 0.5 mL for 1 dose, to be injected preferably into deltoid region Immunisation against Neisseria meningitidis in an unimmunised patient ▶BY INTRAMUSCULAR INJECTION ▶Child 10–17 years: 0.5 mL for 1 dose, booster dose is not required ▶Adult 18–24 years: 0.5 mL for 1 dose, booster dose is not required Immunisation against Neisseria meningitidis in those at risk of exposure ▶BY INTRAMUSCULAR INJECTION ▶Child 1–17 years: 0.5 mL for 1 dose, to be injected preferably into deltoid region (or anterolateral thigh in child 12–23 months), then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of Neisseria meningitidis serogroup A infection ▶Adult: 0.5 mL for 1 dose, to be injected preferably into deltoid region, then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of Neisseria meningitidis serogroup A infection Patients attending university for the first time (who have not received the routine meningococcal groups A with C and W135 and Y conjugate vaccine over the age of 10 years) ▶BY INTRAMUSCULAR INJECTION ▶Adult 18–24 years: 0.5 mL for 1 dose l UNLICENSED USE MENVEO ® ▶In children Menveo ® is not licensed for use in children under 2 years.
PDF page 1407